Turmoil at FDA as Peter Marks Forced Out, Biotech Industry Reels
In a shocking turn of events, Peter Marks, the respected head of the FDA's Center for Biologics Evaluation and Research (CBER), has been forced to resign, sending shockwaves through the pharmaceutical industry. This development, coupled with a wave of layoffs at the Department of Health and Human Services (HHS), has left the biotech sector in disarray and raised serious concerns about the future of drug regulation in the United States.